Abstract
Mechanisms underlying multidrug resistance (MDR), one of the major causes of cancer treatment failure, are still poorly understood. We selected the osteosarcoma MDR HosDXR150 cell line by culturing Hos cells in the presence of increasing doxorubicin doses and showed that it is crossresistant to vinblastine. Similarly to the Hos parental cell line, HosDXR150 cells present mutated p53, functionally inactivated pRb/p105 and wild-type pRb2/p130. Owing to p53 mutation, MDR-1 gene, codifying for P-glycoprotein, is upregulated. Evasion of apoptosis in HosDXR150 cells is only partially explained by drug extrusion because of P-glycoprotein overexpression. Analysis of gene expression level profiles showed that parental cell line undergoes apoptosis through an E2F1/p73-dependent pathway while its resistant variant evades it. This result can be explained by the presence of distinct E2Fs–pRb2/p130 complexes on the p73 promoter. Namely, in Hos p73 transcription is activated by E2F1–Rb2/p130–p300 complexes, while in HosDXR150 it is kept repressed by E2F4–Rb2/p130–HDAC1 complexes.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
An B, Jin JR, Lin P and Dou QP . (1996). FEBS Lett., 399, 158–162.
Bellan C, Lazzi S, Ferrari F, Stumpo M, Bartolomei S, Toti P, Leoncini L, Tosi GM, Cevenini G, Cinti C, Trimarchi C, Giordano, Kraft R, Laissue J and Cottier H . (2002). Inv. Ophthal. Visual Sci., 43, 3602–3608.
Chan HM, Krstic-Demonacos M, Smith L, Demonacos C and LaThangue NB . (2001). Nat Cell Biol., 3, 667–674.
Chen CJ, Chin JE, Ueda K, Clark DP, Pastan I, Gottesmann MM and Roninson IB . (1986). Cell, 47, 381–389.
Cinti C, Claudio PP, De Luca A, Cuccurese M, Howard CM, D'Esposito M, Paggi M, La Sala D, Azzoni L, Halazonetis T, Giordano A and Maraldi NM . (2000). Onocogene, 19, 5098–5105.
Costanzo A, Merlo P, Pediconi N, Fulco M, Sartorelli V, Cole PA, Fontemaggi G, Fanciulli M, Schiltz L, Blandino G, Balsano C and Levrero M . (2002). Mol. Cell., 9, 175–186.
Cress WW and Seto E . (2000). J. Cell Physiol., 184, 1–16.
Dou QP and An B . (1998). Frontiers Biosci., 3, d419–d430.
Dyson N . (1998). Gen. Dev., 12, 2245–2262.
Ferreira R, Magnaghi-Jaulin L, Robin P, Harel-Bellan A and Trouche D . (1998). Proc. Natl. Acad. Sci. USA, 95, 104–193.
Gorlick R, Huvos AG, Heller G, Aledo A, Beardsley GP, Healey JH and Meyers PA . (1999). J. Clin. Oncol., 17, 2781–2788.
Gottesman MM and Pastan I . (1988). Trends Pharmacol. Sci., 9, 54–58.
Hansen MF . (1991). Clin. Orthop., 270, 237–246.
Hiebert SW, Packham G, Strom DK, Haffner R, Oren M, Zambetti G and Cleveland JL . (1995). Mol. Cell. Biol., 15, 6864–6874.
Hsieh JK, Chan FSG, O'Connor DJ, Mittnacht S, Zhong S and Lu X . (1999). Mol. Cell., 3, 181–193.
Hsieh JK, Fredersdorf S, Kauzarides T, Martin K and Lu X . (1997). Genes Dev., 11, 1840–1852.
Irwin M, Marin MC, Phillips AC, Seelan RS, Smith DI, Liu W, Flores ER, Tsai KY, Jacks T, Vousden KH and Kaelin Jr WG . (2000). Nature, 407, 645–648.
Johnson DG . (1995). Oncogene, 11, 1685–1692.
Johnson DG and Schneider-Broussard R . (1998). Front. Biosci., 3, d447–d448.
Kane SE, Pastan I and Gottesman MM . (1990). J. Bioenerg. Biomembr., 22, 593–618.
Kowalik TF, DeGregori J, Leone G, Jakoi L and Nevins JR . (1998). Cell. Growth Differ., 9, 113–118.
Lavia P and Jansen-Durr P . (1999). BioEssay, 21, 221–230.
Lin X, Dowjat WK and Costa M . (1994). Cancer Res., 54, 2751–2754.
Macaluso M, Cinti C, Russo G, Russo A and Giordano A . (2003). Oncogene 22, 3511–3517.
Miller CW, Aslo A, Won A, Tan M, Lampkin B and Koeffler HP . (1996). J. Cancer Res. Clin. Oncol., 122, 559–565.
Moroni MC, Hickman ES, Denchi LE, Caprara G, Colli E, Cecconi F, Muller H and Helin K . (2001). Nat. Cell. Biol., 3, 552–558.
Nguyen KT, Liu B, Ueda K, Gottesman MM, Pastan I and Chin KV . (1994). Oncol. Res., 6, 71–77.
Oda Y, Matsumoto Y, Harimaya K, Iwamoto Y and Tsuneyoshi M . (2000). Oncol. Rep., 7, 859–866.
Orlando V, Strutt H and Paro R . (1997). Methods, 11, 205–214.
Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, Chen DL and Koeffler HP . (1994). Oncogene, 9, 1899–1906.
Pucci B, Claudio PP, Masciullo V, Bellincampi L, Terrinoni A, Khalili K, Melino G and Giordano A . (2002). Oncogene, 21, 5897–5905.
Rayman JB, Takahashi Y, Indjeian VB, Dannenberg JH, Catchpole S, Watson RJ, Riele H and Dynlacht BD . (2002). Gen. Dev., 16, 933–947.
Ren B, Cam H, Takahashi Y, Volkert T, Terragni J, Young RA and Dynlacht BD . (2002). Gen. Dev., 16, 245–256.
Seelan RS, Irwin M, van der Stoop P, Qian C, Kaelin Jr WG and Liu W . (2002). Neoplasia., 4, 195–203.
Serra M, Scotlandi K, Manara MC, Maurici D, Lollini PL, De Giovanni C, Toffoli G and Baldini N . (1993). Anticancer Res., 13, 323–329.
Shnyder SD, Hayes AJ and Pringle J . (1998). Br. J. Cancer, 78, 757–759.
Sigal A and Rotter V . (2000). Cancer Res., 60, 6788–6793.
Somasundaram K and El-Deiry WS . (2000). Front. Biosci., 5, d424–d437.
Stiewe T and Putzer BM . (2000). Nat. Genet., 26, 464–469.
Strauss BE and Haas M . (1995). Biochem. Biophys. Res. Commun., 217, 333–340.
Strauss BE, Shivakumar C, Deb SP, Deb S and Haas M . (1995). Biochem. Biophys. Res. Commun., 217, 825–831.
Takahashi Y, Rayman JB and Dynlacht BD . (2000). Gen. Dev., 14, 804–816.
Thottassery JV, Zambetti GP, Arimori A, Shuetz EG and Shuetz JD . (1997). Proc. Natl. Acad. Sci. USA, 94, 11037–11042.
Vogelstein B, Lane D and Levine AJ . (2000). Nature, 408, 307–310.
Weinberg RA . (1995). Ann. NY Acad. Sci., 758, 331–338.
Zaika A, Irwin M, Sansome C and Moll UM . (2001). J. Biol. Chem., 276, 11310–11316.
Zini N, Trimarchi C, Claudio PP, Stiegler P, Marinelli F, Maltarello MC, La Sala D, De Falco G, Russo G, Ammirati G, Maraldi NM, Giordano A and Cinti C . (2001). J. Cell Physiol., 89, 34–44.
Acknowledgements
We are grateful to Dr Fiorenzo Marinelli for the helpful and constructive comments on the manuscript and Dr Massimo Riccio for helping in the acquisition of confocal laser scanning images. This work was supported by CNR grant, MURST-LAG-CO3 grant, Sbarro health Research Organization and NIH grants.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
La Sala, D., Macaluso, M., Trimarchi, C. et al. Triggering of p73-dependent apoptosis in osteosarcoma is under the control of E2Fs–pRb2/p130 complexes. Oncogene 22, 3518–3529 (2003). https://doi.org/10.1038/sj.onc.1206487
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206487
Keywords
This article is cited by
-
In vivo and in vitro inhibition of osteosarcoma growth by the pan Bcl-2 inhibitor AT-101
Investigational New Drugs (2020)
-
RBL2/p130 is a direct AKT target and is required to induce apoptosis upon AKT inhibition in lung cancer and mesothelioma cell lines
Oncogene (2018)
-
Downregulation of PARP1 transcription by promoter-associated E2F4-RBL2-HDAC1-BRM complex contributes to repression of pluripotency stem cell factors in human monocytes
Scientific Reports (2017)
-
Pathway landscapes and epigenetic regulation in breast cancer and melanoma cell lines
Theoretical Biology and Medical Modelling (2014)
-
Rb family proteins as modulators of gene expression and new aspects regarding the interaction with chromatin remodeling enzymes
Oncogene (2006)